Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 10693.154 | 0.9689 | 0.9287 | 0.8696 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 10693.154 | 0.9690 | 0.9288 | 0.8696 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 10693.154 | 0.9918 | 0.9812 | 0.8696 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 10693.154 | 0.9379 | 0.8579 | 0.8696 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 10693.154 | 0.7912 | 0.5277 | 0.8696 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 10693.154 | 0.6818 | 0.2876 | 0.8696 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 10693.154 | 0.5084 | -0.0813 | 0.8696 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 10693.154 | 0.0538 | -0.9305 | 0.8696 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 11936.154 | 0.9438 | 0.8647 | 0.8259 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 11936.154 | 0.9128 | 0.7909 | 0.8259 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 11936.154 | 0.9257 | 0.8216 | 0.8259 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 11936.154 | 0.9509 | 0.8816 | 0.8259 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 11936.154 | 0.8276 | 0.5904 | 0.8259 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 11936.154 | 0.7668 | 0.4502 | 0.8259 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 11936.154 | 0.6177 | 0.1162 | 0.8259 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 11936.154 | 0.5056 | -0.1242 | 0.8259 | |
| HCC1428 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 11936.154 | 0.0538 | -0.9419 | 0.8259 | |
| HCC1569 | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 10872.154 | 1.0581 | 1.0824 | 1.3976 | |
| HCC1569 | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 10872.154 | 1.1223 | 1.1721 | 1.3976 | |
| HCC1569 | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 10872.154 | 1.0087 | 1.0125 | 1.3976 | |
| HCC1569 | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 10872.154 | 1.0642 | 1.0911 | 1.3976 | |
| HCC1569 | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 10872.154 | 1.0462 | 1.0657 | 1.3976 | |
| HCC1569 | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 10872.154 | 0.9026 | 0.8587 | 1.3976 | |
| HCC1569 | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 10872.154 | 0.4980 | 0.2145 | 1.3976 | |
| HCC1569 | HER2amp | Basal A | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 10872.154 | 0.2975 | -0.1601 | 1.3976 |